“Mild clinical course of COVID-19 infection in chronic myeloid leukemia (CML) patients receiving tyrosine kinase inhibitors (TKIs) without interruption” (2021) Mediterranean Journal of Hematology and Infectious Diseases, 13(1), p. e2021022. doi:10.4084/mjhid.2021.022.